Fauci
says pause on J&J COVID-19 shot should not prompt vaccine hesitancy
Send a link to a friend
[April 15, 2021]
By Carl O'Donnell and Jarrett Renshaw
(Reuters) - Top U.S. health officials urged
Americans to get vaccinated against COVID-19 on Wednesday, saying U.S.
regulators' pause on Johnson & Johnson shots, following reports it can
cause blood clotting, should boost confidence in the vaccines' safety.
|
U.S. federal health agencies on Tuesday recommended pausing use of
J&J's COVID-19 vaccine for at least a few days after six women under
50 developed rare blood clots after getting the shot.
White House COVID-19 response coordinator Jeff Zients said that U.S.
regulators' quick response to the clotting reports should give
Americans more confidence, not less, that any shots they receive
will be safe.
"We believe that by empowering Americans with data and facts, we
will strengthen the public's trust in government, and increased
their confidence in the vaccines," said Zients at a press briefing
on Wednesday.
Zients said the White House had taken action to speed up production
and delivery schedules for Moderna Inc and Pfizer Inc vaccines in a
bid to offset the pause in J&J dose shipments and maintain the pace
of the United States' inoculation program.
[to top of second column] |
He said J&J shots have so far
made up less than 5% of the more than 190
million COVID-19 vaccine doses that have been
administered in the United States as of Tuesday.
"People who have vaccine appointments to receive
(Pfizer and Moderna) vaccines should keep their
appointments, and we will work with our partners
across the country to reschedule those who are
intending to get the Johnson and Johnson
vaccine," U.S. Centers of Disease Control and
Prevention Director Dr. Rochelle Walensky said
on Wednesday.
The United States vaccine rollout is
accelerating, Zients said, with providers now
administering around 3.3 million shots daily on
average.
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |